News and Trends 23 Nov 2022 UCB publishes Lennox-Gastaut syndrome study data …study also demonstrated that FINTEPLA was generally well tolerated. The most common treatment-emergent adverse events observed in the OLE were decreased appetite, fatigue, nasopharyngitis, and seizure. The cardiovascular safety in… November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2017 Bioart from the Ocean Depths: Underwater Sounds …are still songs to sing beyond mankind.” https://vimeo.com/126787314 Upcoming events by Robertina Šebjanič Performance: Aquatocene / Subaquatic quest for serenity Tesla Award at City Museum Ljubljana, Slovenia 8 November Exhibition:… November 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 18 Feb 2025 T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments …approval was a “watershed moment,” according to Paul Burton, chief medical officer (CMO) of Amgen, in an interview with Fierce Biotech last year. Also calling it a “significant milestone for… February 18, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 Feb 2018 New Antiviral for RSV Lung Infections Shows Promise in Phase IIa ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs,… February 5, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2023 AbbVie takes step forward in Europe with migraine drug …mg QD was well tolerated and the most common adverse events were constipation, nausea, and fatigue. The adverse drug reaction most commonly leading to study discontinuation was nausea (0.4%). “Far… June 26, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2025 Akribion Therapeutics emerges from stealth with programmable cell depletion RNA technology Today, Akribion Therapeutics, a German biotech company announced its €8 million ($8.2 million) seed round. Akribion Therapeutics is working on G-dase E, a programmable nuclease designed to selectively deplete specific… February 4, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by BeOne Medicines 26 Jun 2025 How can treatment strategies evolve to address the challenges in chronic lymphocytic leukemia? …≥3 adverse events for zanubrutinib (greater than 10%) were neutropenia and hypertension. Driving what’s next While some patients find freedom in continuous treatment, others seek a different kind of freedom… June 26, 2025 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 13 Jun 2022 DNA synthesis: tackling the main bottleneck in biology research …Bioscience, Molecular Assemblies, Ansa Biotechnologies and GenScript. Bringing DNA synthesis to the benchtop The restrictions of chemical DNA synthesis methods currently in use have meant that in most labs, writing… June 13, 2022 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 Korean researchers develop antimicrobial peptides discovery tool …microorganisms as a natural defense against infections. AMPs combat harmful bacteria via a nonspecific mechanism that prevents them from developing antimicrobial resistance. Despite these abilities, research on AMPs is being… February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 This Gene Therapy for Hemophilia Can Reduce Bleeding by 70% …uniQure might still struggle to compete with another gene therapy for hemophilia B being developed by Spark Therapeutics. The US biotech published Phase I/II clinical data this month revealing that… December 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 May 2018 Top Medical Devices Bringing Innovation to Europe in 2018 …pipeline. BASF, the largest chemical producer, is collaborating with the French biotech bioprinting companies Poietis and CtiBiotech to improve its skin models for drug testing. But while simple models of… May 28, 2018 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials …neurofibrillary tangles, made up of tau aggregates, in the brain — a feature that it shares with Alzheimer’s disease. Inhibition of the O-GlcNAcase enzyme prevents certain sugar residues from being… April 6, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email